JP4629308B2 - リポソーム - Google Patents

リポソーム Download PDF

Info

Publication number
JP4629308B2
JP4629308B2 JP2002586908A JP2002586908A JP4629308B2 JP 4629308 B2 JP4629308 B2 JP 4629308B2 JP 2002586908 A JP2002586908 A JP 2002586908A JP 2002586908 A JP2002586908 A JP 2002586908A JP 4629308 B2 JP4629308 B2 JP 4629308B2
Authority
JP
Japan
Prior art keywords
liposomes
liposome
cholesterol
dspc
dmpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002586908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529163A (ja
JP2004529163A5 (https=
Inventor
シグリッド・フォスハイム
リヴ・イングリッド・オデガルドストゥエン
Original Assignee
ジーイー・ヘルスケア・アクスイェ・セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーイー・ヘルスケア・アクスイェ・セルスカプ filed Critical ジーイー・ヘルスケア・アクスイェ・セルスカプ
Publication of JP2004529163A publication Critical patent/JP2004529163A/ja
Publication of JP2004529163A5 publication Critical patent/JP2004529163A5/ja
Application granted granted Critical
Publication of JP4629308B2 publication Critical patent/JP4629308B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2002586908A 2001-05-10 2002-05-10 リポソーム Expired - Fee Related JP4629308B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes
PCT/GB2002/002100 WO2002089771A1 (en) 2001-05-10 2002-05-10 Liposomes

Publications (3)

Publication Number Publication Date
JP2004529163A JP2004529163A (ja) 2004-09-24
JP2004529163A5 JP2004529163A5 (https=) 2005-12-22
JP4629308B2 true JP4629308B2 (ja) 2011-02-09

Family

ID=9914262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586908A Expired - Fee Related JP4629308B2 (ja) 2001-05-10 2002-05-10 リポソーム

Country Status (8)

Country Link
US (1) US20040170560A1 (https=)
EP (1) EP1385480B1 (https=)
JP (1) JP4629308B2 (https=)
AT (1) ATE430557T1 (https=)
DE (1) DE60232237D1 (https=)
ES (1) ES2323493T3 (https=)
GB (1) GB0111279D0 (https=)
WO (1) WO2002089771A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317882A (pt) * 2002-12-31 2005-12-13 Bharat Serums & Vaccines Ltd Processo para fabricação de lipossomas de longa circulação não tratados com peg; lipossoma; composição de doxorrubicina lipossomal de longa duração não tratada com peg; e método
ATE470435T1 (de) * 2003-11-03 2010-06-15 Yissum Res Dev Co Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
KR101975843B1 (ko) * 2008-05-23 2019-05-09 더 유니버시티 오브 브리티쉬 콜롬비아 리포좀 나노입자에 사용하기 위한 변형된 약물
EP2342340A1 (en) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
JP5854559B2 (ja) * 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
BR112013027413A2 (pt) * 2011-04-26 2019-09-24 Cedars Sinai Medical Center vancomicina lipossomal para o tratamento de infecções de sarm.
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) * 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CR20170181A (es) 2014-10-06 2017-05-31 Exicure Inc Compuestos anti-tnf
US10517924B2 (en) 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
CN105434368A (zh) * 2014-11-27 2016-03-30 广州白云山明兴制药有限公司 一种注射用还原型谷胱甘肽及其预冻方法
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137735A (ja) * 1984-07-31 1986-02-22 Terumo Corp ヘモグロビン含有リポソ−ムおよびその製造方法
EP0469082B1 (en) * 1989-04-18 1995-04-05 Vestar, Inc. Liposomal targeting of ischemic tissue
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
WO1996032930A1 (en) * 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
JPH11171772A (ja) * 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
DE60008234T2 (de) * 1999-04-29 2004-12-30 Alza Corp., Mountain View Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
AU6142700A (en) * 1999-07-07 2001-01-30 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Delivery of liposomal-encapsulated antioxidants and applications thereof

Also Published As

Publication number Publication date
WO2002089771A1 (en) 2002-11-14
ES2323493T3 (es) 2009-07-17
EP1385480B1 (en) 2009-05-06
US20040170560A1 (en) 2004-09-02
DE60232237D1 (de) 2009-06-18
GB0111279D0 (en) 2001-06-27
EP1385480A1 (en) 2004-02-04
JP2004529163A (ja) 2004-09-24
ATE430557T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
JP4629308B2 (ja) リポソーム
Phillips Delivery of gamma-imaging agents by liposomes
Boerman et al. Radiolabeled liposomes for scintigraphic imaging
US5415867A (en) High ratio active agent: lipid complex
US6207133B1 (en) Anti-tumoral therapy agent containing a contrast agent
US5143713A (en) 99m Tc labeled liposomes
JPS63233915A (ja) 両親媒性物質会合活性成分を取り込んだ運搬担体
JP3010500B2 (ja) 虚血性組織のリポゾームターゲッティング
Oku Delivery of contrast agents for positron emission tomography imaging by liposomes
CA2394717C (en) Iron chelator delivery system
DE4341472A1 (de) Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
ES2314977T3 (es) Agentes radioterapeuticos que contienen estaño-117m.
CA2583367A1 (en) Cytotoxic formulation for combination therapy
US6274115B1 (en) Method of targeting a specific location in a body using phospholipid and cholesterol liposomes which encapsulate an agent
AU2019289884B2 (en) Composition containing a somatostatin analogue for radiopharmaceutical use
JPH05271102A (ja) 放射性薬剤の制菌剤
Ogihara-Umeda et al. Increased delivery of gallium-67 to tumors using serum-stable liposomes
Seltzer et al. Contrast material-carrying liposomes: biodistribution, clearance, and imaging characteristics.
US8029795B2 (en) Targeted iron chelator delivery system
Cevc Drug-carrier and stability properties of the long-lived lipid vesicles. Cryptosomes, in vitro and in vivo
EP0414806A1 (en) ACTIVE AGENT COMPLEX: LIPID WITH HIGH RATIO.
US20240156996A1 (en) Biocompatible radionuclide-containing compositions and methods of use
Laverman et al. Radiolabeling of liposomes for scintigraphic imaging
TWI278321B (en) Stabiliser for radiopharmaceuticals
JPH0747533B2 (ja) 体内腫瘍の目標攻撃、診断または治療用ミセル粒子組成物

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20041124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20041209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100616

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101012

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131119

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees